Drug Database
AN

anti-H5N1 avian influenza antibodies (Fabenflu / FBF001)

✓ Approved

Fab'entech · Polyclonal Antibodies · Polyclonal Antibodies

What is anti-H5N1 avian influenza antibodies?

anti-H5N1 avian influenza antibodies is a polyclonal antibodies developed by Fab'entech. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesFabenflu, FBF001
CompanyFab'entech
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Therapeutic Indications

anti-H5N1 avian influenza antibodies is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsInfluenza✓ Approved

Related Research Articles

PubMedNpj viruses2026-11-12

Penetration of avian and human influenza A viruses through mucus gel networks in vitro.

Rohde Maximilian M, Riegel Fiona F, Duran Ege E, Butnarasu Cosmin Stefan CS et al.

Influenza A viruses (IAVs) remain a public-health concern because of their continuous evolution and zoonotic transmission. Respiratory mucus is the first extracellular barrier encountered by inhaled viruses, yet standardized approaches for studying influenza virus passage through mucus and the infectivity of transferred virus populations remain limited. Here, we established an in vitro virus-mucus penetration assay to analyze IAV interactions with standardized mucin-containing matrices. We used mucus from human Calu-3 airway epithelial cells cultured under air-liquid interface conditions and bovine submaxillary mucin as surrogate matrices. Preparations were normalized by total protein and characterized using biochemical and biophysical methods. We compared a human seasonal H1N1pdm virus with a highly-pathogenic avian H5N1 virus. Viral genome transfer was quantified by RT-qPCR, while retained infectivity was assessed in susceptible cells. Both mucin-containing matrices restricted viral passage compared with control solutions. Viral RNA transfer and retained infectivity varied by matrix and virus, although no statistically significant difference between H1N1pdm and H5N1 was detected within either matrix. Together, these results establish a framework integrating mucus characterization with complementary measurements of viral transfer and infectivity. This approach provides a basis for investigating influenza virus-mucus interactions under controlled conditions and can be extended to other IAV strains and physiologically relevant mucus sources.

PubMedVector borne and zoonotic diseases (Larchmont, N.Y.)2026-11-12

Heterogeneous Permissiveness of Chicken Cells and Tissues to Oropouche Viruses.

Limonta Daniel D, Salas-Quinchucua Cristhian C, Knuese Cole C, Lopez-Carvajal Maria Stella MS et al.

Massive outbreaks of a reassortant Oropouche virus (OROV) spread across Latin America and the Caribbean in 2023-2025. OROV is a reemerging arbovirus belonging to the trisegmented RNA peribunyavirus family. Viral transmission occurs in sylvatic and urban cycles involving humans and other vertebrates with Culicoides biting midges as the main vector in urban settings. Anti-OROV antibodies have been found in domestic and wild birds in Brazilian OROV-endemic areas. However, no studies exist on the permissiveness of OROV in avian models, and the contribution of birds to the OROV spread remains largely unexplored. Our research indicates that chicken embryonic fibroblasts and chicken tissue explants from the liver, heart, and lung are selectively infected by OROV strains isolated by our group in South America, including the novel OROV reassortant. This work contributes to the development of avian models to investigate new determinants in the infection and transmission of an important arbovirus in the Americas.

PubMedBMC research notes2026-11-12

Seroprevalence of cytomegalovirus IgG and IgM antibodies and associated factors among women with spontaneous abortion in Lahj Governorate, Yemen.

Gubran Ali N M ANM, Masood Marwa Mohammed S MMS, Qasim Alaa Hatem Othman AHO, Ali Eglal Yones Abdulwali EYA et al.

This study aimed to determine the seroprevalence of anti-CMV IgG and anti-CMV IgM antibodies among women with spontaneous abortion in Lahj Governorate, Yemen. An analytical cross-sectional study was among 110 women with spontaneous abortion. Five milliliters of blood were collected from women, sera were separated, and anti-CMV IgG and IgM were determined using a Cobas® e 411 analyzer that is based on electrochemiluminescence immunoassay (ECLIA). The data were entered and then analyzed using SPSS. Associations were assessed using the chi-square test, and prevalence ratios (PR) with 95% confidence intervals (CIs) were calculated. The seroprevalence of anti-CMV IgG and IgM antibodies was 80.9% and 7.3%, respectively. A statistically significant association was observed between anti-CMV IgM seropositivity and having experienced two previous spontaneous abortions (PR = 5.0, 95% CI: 1.13-21.97; p = 0.042). A high seroprevalence of CMV IgG antibodies and low IgM seropositivity among women with spontaneous abortion in Lahj, Yemen.

PubMedExpert opinion on therapeutic patents2026-11-12

A patent review of anti‑VEGF antibodies for the treatment of ocular diseases (2020-present).

Panos Georgios D GD

Anti-VEGF therapy remains central to the management of neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion, but treatment burden and limited durability remain major unmet needs. This review examines how recent patenting has shifted from first-generation anti-VEGF binders toward approaches designed to extend intraocular durability and strengthen product differentiation. This article reviews the patent landscape for antibody-based VEGF inhibition in ophthalmology from 1 January 2020 to 18 September 2026. Patent databases of the World Intellectual Property Organization (WIPO), US Patent and Trademark Office (USPTO), European Patent Office (EPO), Japan Patent Office (JPO), and China National Intellectual Property Administration (CNIPA) were searched for composition-of-matter, formulation, method-of-treatment, and delivery claims. The review covers bispecific antibodies, antibody-biopolymer conjugates, gene-encoded antibody fragments, and high-concentration ophthalmic formulations, with relevant clinical programs used to provide context. Anti-VEGF antibody patenting is now driven mainly by durability rather than by new binding targets alone. Over the next few years, competitive advantage is likely to depend on the successful integration of molecular format, formulation, delivery, and manufacturability into clinically reliable long-acting products.

PubMedCancer discovery2026-11-12

Anti-CAR Antibodies May Undermine Cell Therapy in Brain Tumors.

Chimeric antigen receptor T-cell therapies for brain tumors have shown limited durability, in part because of an antibody attack on the engineered receptor itself, new research shows. Suppressing that response, either with preconditioning drugs or by redesigning the chimeric antigen receptor, helps make the cells and their therapeutic benefit last.

PubMedJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2026-11-12

Correlation of seasonal influenza rates with hospital-acquired Clostridioides difficile rates: Implications for research and interventions for prevention.

Faris Peter P, Leal Jenine J, Lamont Nicole N, Ocampo Wrechelle W et al.

Hospital-acquired Clostridioides difficile infection (HA-CDI) rate variability can create challenges for assessing interventions that might improve rates. We therefore sought to assess whether seasonal trends in HA-CDI could be related to influenza rates by examining the sensitivity and applicability of statistical methods that identify seasonal trend associations. We assessed HA-CDI rates per 10,000 patient-days and influenza hospitalizations per 1,000 admissions in four acute care facilities from January 2016 to December 2018. Four statistical approaches were used in R (4.5.1) including (1) autoregressive integrated moving average (ARIMA); (2) cross-correlation to assess if dependencies lagged over time; (3) Poisson harmonic regression to model cyclical trends; and (4) Poisson harmonic regression models including influenza rates. ARIMA approaches did not detect seasonality in HA-CDI rates, but found strong seasonality in the influenza rates, whereas cross-correlation analysis found evidence of correlation between the series at a lag of zero (R = 0.41, 95% CI 0.08 to 0.65) and provided an indication of a seasonal relationship. Poisson harmonic regression for trends suggested that influenza rates predicted CDI rates (p < 0.01), whilst Poisson harmonic regression identified evidence of seasonality in HA-CDI rates (p < 0.05) and influenza rates (p < 0.001). Poisson harmonic regression provided a sensitive means of identifying seasonality in HA-CDI rates with the seasonality effect being accounted for by influenza admission rates, which may be mediated by inappropriate antibiotic prescriptions. This observation may be useful in interpreting future interventions to reduce HA-CDI.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-H5N1 avian influenza antibodies